步长制药：8月7日召开董事会会议

Core Viewpoint - The company announced the convening of its 28th meeting of the fifth board of directors on August 7, 2025, to discuss various proposals, including a significant agreement with GOODFELLOW regarding the injectable Efparepoetinalfa [2] Company Summary - The company reported that for the year 2024, its revenue composition was 99.71% from the pharmaceutical industry and 0.29% from other businesses [2]